What is the FDA’s current stance on compounded GLP-1s?
The FDA is actively cracking down on the mass‑marketing of compounded GLP‑1 products, especially by telehealth and online platforms that make false or misleading claims suggesting their products are equivalent to FDA‑approved drugs. Current FDA communications and policy clarifications emphasize that shortage‑based flexibilities for compounding these medicines are being phased out as branded GLP‑1 products come off the drug shortage list, with only limited 503A/503B exemptions remaining for patients whose needs cannot be met by commercially available options.
How does Foundayo (orforglipron) differ from other oral GLP-1s?
Unlike existing oral GLP‑1 formulations that require patients to follow strict fasting and water‑intake rules before and after taking the pill, Foundayo (orforglipron) is a once‑daily oral GLP‑1 receptor partial agonist that can be taken at any time of day, with or without food and water. This flexibility reduces the dosing burden and may improve adherence for patients who struggle with the rigid administration requirements of earlier oral GLP‑1 options.
Why do most patients stop taking GLP-1 medications?
Although side effects receive a great deal of attention, real‑world data indicate that cost is the leading reason patients discontinue GLP‑1 therapy. Financial barriers account for nearly half of all discontinuations in some cohorts, far outweighing discontinuation due to adverse effects or perceived lack of efficacy, which underscores the importance of proactively addressing affordability and coverage when initiating treatment.
What is the Medicare BALANCE model for GLP-1s?
The Building and Renewing Access for Coverage and Equity (BALANCE) model includes a temporary Medicare GLP‑1 Bridge designed to expand short‑term access to obesity medications. Beginning July 1, 2026, this bridge will provide eligible Medicare Part D enrollees with time‑limited access to select GLP‑1s for obesity through December 2026, with some plan designs expected to cap out‑of‑pocket costs at around $50 per month, depending on how individual plans implement the model.
Do GLP-1s cause disproportionate muscle loss?
Recent data suggest that although GLP‑1‑induced weight loss does reduce absolute lean mass, it does not appear to cause a disproportionate loss of muscle mass or physical function relative to the amount of fat lost in the middle‑aged adults and animal models studied so far. However, other research highlights that a meaningful fraction of weight lost with GLP‑1 therapy can be lean tissue, and the impact in older, frail, or sarcopenia‑prone patients remains a concern.
Clinicians should continue to emphasize adequate protein intake and regular resistance training for all patients on GLP‑1s—particularly older adults and postmenopausal women—to help preserve muscle mass and function during rapid weight reduction.
